Oxycodone: A Pain-Relieving Agent With Cardioprotective Properties Against Myocardial Ischemia–Reperfusion Injury

IF 2.8 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Mehdi Dehghani Firoozabadi, Behrang Nooralishahi, Fatemeh Rezaei-Tazangi
{"title":"Oxycodone: A Pain-Relieving Agent With Cardioprotective Properties Against Myocardial Ischemia–Reperfusion Injury","authors":"Mehdi Dehghani Firoozabadi,&nbsp;Behrang Nooralishahi,&nbsp;Fatemeh Rezaei-Tazangi","doi":"10.1155/cdr/6182342","DOIUrl":null,"url":null,"abstract":"<p>In the realm of cardiovascular diseases, myocardial ischemia–reperfusion injury (MIRI) is known as one of the main life-threatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the anti-MIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12903989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/6182342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

In the realm of cardiovascular diseases, myocardial ischemia–reperfusion injury (MIRI) is known as one of the main life-threatening conditions with significant morbidity and mortality. Although some therapeutic approaches, like pharmacological treatments and ischemic preconditioning, have been suggested for MIRI, offering a functional approach with high effectiveness for MIRI remains challenging. Recent studies have indicated that oxycodone, a semisynthetic opioid used to improve acute to chronic pain, may be cardioprotective against MIRI. The current experimental evidence showed that these protective influences can stem from the ability of oxycodone to regulate apoptosis, inflammation, and oxidative stress, as well as promote cardiovascular parameters (e.g., infarct size, cardiac function, and endothelial integrity). Hence, the main purpose of this narrative review study is to summarize and discuss the anti-MIRI potential of oxycodone with a mechanistic insight. This narrative review was also conducted to hold promise for researchers and clinicians to consider and assess its clinical capacity for subjects suffering from this challenging disease.

Abstract Image

羟考酮:一种对心肌缺血再灌注损伤具有心脏保护作用的止痛剂。
在心血管疾病领域,心肌缺血再灌注损伤(MIRI)是危及生命的主要疾病之一,具有很高的发病率和死亡率。虽然一些治疗方法,如药物治疗和缺血预处理,已经被建议用于MIRI,但提供一个高效的功能性方法仍然具有挑战性。最近的研究表明,羟考酮是一种半合成阿片类药物,用于改善急性到慢性疼痛,可能对MIRI具有心脏保护作用。目前的实验证据表明,这些保护作用可能源于氧可酮调节细胞凋亡、炎症和氧化应激的能力,以及促进心血管参数(如梗死面积、心功能和内皮完整性)。因此,本叙述性综述研究的主要目的是总结和讨论羟考酮的抗miri潜力,并从机理上进行探讨。这篇叙述性综述也为研究人员和临床医生提供了希望,以考虑和评估其对患有这种具有挑战性疾病的受试者的临床能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Therapeutics
Cardiovascular Therapeutics 医学-心血管系统
CiteScore
5.60
自引率
0.00%
发文量
55
审稿时长
6 months
期刊介绍: Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书